See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Sudeep Shivakumar

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	38262288	0	Abdulrehman J, Harrigan A, Simard C, et al. TRanEXamic acid to decrease Heavy Menstrual Bleeding in individuals anticoagulated for venous thromboembolism (T-REX HMB): Health care practitioner survey. Thromb Res. 2024 Jan 17;235:11-14. doi: 10.1016/j.thromres.2024.01.009.
	37722206	0	Tathireddy H, Rice D, Martens K, et al. Breaking down tumor thrombus: Current strategies for medical management. Thromb Res. 2023 Sep 13;230:144-151. doi: 10.1016/j.thromres.2023.09.004.
	37121015	0	Potere N, Di Nisio M, Porreca E, et al. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. Thromb Res. 2023 Apr 26;226:82-85. doi: 10.1016/j.thromres.2023.04.015.
	36809776	0	Pradier M, Rodger MA, Ghanima W, et al. Performance and head-to head comparison of three clinical models to predict occurrence of post-thrombotic syndrome. A validation study. Thromb Haemost. 2023 Feb 21. doi: 10.1055/a-2039-3388.
	36315952	0	Shivakumar S. In acutely ill inpatients, benefits and harms of anticoagulants for VTE prophylaxis were assessed. Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0089.
	36135074	0	Harrigan AM, Rioux J, Shivakumar S. Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner. Curr Oncol. 2022 Sep 8;29(9):6419-6432. doi: 10.3390/curroncol29090505.
	35660801	0	Brandt W, Brown C, Wang TF, et al. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thromb Res. 2022 May 29;216:8-10. doi: 10.1016/j.thromres.2022.05.014.
	35587536	0	Popov J, Coelho S, Carrier M, et al. Step down to six months of prophylactic-dose low-molecular-weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): a pilot study. J Thromb Haemost. 2022 May 19. doi: 10.1111/jth.15760.
	35344784	0	Delluc A, Ghanima W, Kovacs MJ, et al. Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER). Thromb Res. 2022 Mar 19;213:119-124. doi: 10.1016/j.thromres.2022.03.014.
	35021257	0	Ng S, Rodger MA, Ghanima W, et al. External validation of the patient reported Villalta scale for the diagnosis of post-thrombotic syndrome. Thromb Haemost. 2022 Jan 12. doi: 10.1055/a-1738-1313.
	34940092	0	Carrier M, Blais N, Crowther M, et al. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Curr Oncol. 2021 Dec 18;28(6):5434-5451. doi: 10.3390/curroncol28060453.
	34807722	0	Le Gal G, Kovacs MJ, Bertoletti L, et al. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-2981.
	34564938	0	Delluc A, Ghanima W, Kovacs MJ, et al. Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. J Thromb Haemost. 2021 Sep 26. doi: 10.1111/jth.15537.
	34518263	0	Galanaud JP, Abdulrehman J, Lazo-Langner A, et al. MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. BMJ Open. 2021 Sep 13;11(9):e049557. doi: 10.1136/bmjopen-2021-049557.
	32346486	0	Legault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud. 2020 Apr 25;6:52. doi: 10.1186/s40814-020-00594-1. eCollection 2020.
	32211571	0	Kahn SR, Shivakumar S. What's new in VTE risk and prevention in orthopedic surgery. Res Pract Thromb Haemost. 2020 Mar 9;4(3):366-376. doi: 10.1002/rth2.12323. eCollection 2020 Mar.
	31380891	0	Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431.
	30511879	0	Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4.
	29353682	0	van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thromb Res. 2018 Mar;163:41-46. doi: 10.1016/j.thromres.2018.01.009. Epub 2018 Jan 9.
	29310057	0	Skeith L, Carrier M, Shivakumar S, et al. Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. Thromb Res. 2018 Feb;162:79-86. doi: 10.1016/j.thromres.2017.12.008. Epub 2017 Dec 13.
	29212129	0	Douketis JD, Spyropoulos AC, Anderson JM, et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553. Epub 2017 Dec 6.
	28680172	0	Al Saleh AS, Berrigan P, Anderson D, et al. Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation. Can J Hosp Pharm. 2017 May-Jun;70(3):188-199. doi: 10.4212/cjhp.v70i3.1658. Epub 2017 Jun 30.
	28160670	0	Coyle K, Carrier M, Lazo-Langner A, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017 Mar;151:67-71. doi: 10.1016/j.thromres.2017.01.007. Epub 2017 Jan 25.
	27031923	0	Gauthier K, Le Gal G, Shivakumar S, et al. Inter-observer reliability of the HERDOO2 clinical decision rule. Thromb Res. 2016 May;141:136-8. doi: 10.1016/j.thromres.2016.03.015. Epub 2016 Mar 15.
	26817957	0	Ihaddadene R, Corsi DJ, Lazo-Langner A, et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood. 2016 Apr 21;127(16):2035-7. doi: 10.1182/blood-2015-11-682963. Epub 2016 Jan 27.
	26095467	0	Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 Aug 20;373(8):697-704. doi: 10.1056/NEJMoa1506623. Epub 2015 Jun 22.
	25966905	0	Schulman S, Carrier M, Lee AY, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. Circulation. 2015 Jul 21;132(3):167-73. doi: 10.1161/CIRCULATIONAHA.115.015688. Epub 2015 May 12.